Media Release Subcutaneous EPKINLYTM (epcoritamab) is the first and only bispecific antibody approved in Japan…
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company…
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company…
Reports suggest that 400 million Americans go on long distance business trips annually, and with…
Company Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall…
Sanofi announces changes to its Executive Committee Paris, August 31st, 2023. Sanofi announces the following…
Sanofi announces changes to its Executive Committee Paris, August 31st, 2023. Sanofi announces the following…
Media Release COPENHAGEN, Denmark; August 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its…
By Ben Pippenger, CSO at Zylo Managing software can pose a real challenge for organizations….
Significant pipeline advancement highlighted by the initiation of BNT316/ONC-392 Phase 3 pivotal trial and multiple…
August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30,…
August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30,…
Company Announcement COPENHAGEN, Denmark; July 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its…
Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase…
Insider threat can be described as the potential of an employee to utilize their authorised…
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and…
Media Release COPENHAGEN, Denmark; June 22, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that…
— VASCEPA® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an…
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance,…
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance,…